The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COMy 2022 | How the management of high-risk myeloma patients has changed over the years
Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, shares some insights into treatment options for patients with high-risk multiple myeloma, and how this has advanced in recent years. Prof. Mohty first explains that high-risk patients were once an unmet need in myeloma, and then goes on to discuss how combining anti-CD38 antibodies with proteasome inhibitors (PIs) and immunomodulatory imide drugs (IMiDs) has been beneficial. To conclude, Prof. Mohty shares some insights into the efficacy of combination therapy for patients who are transplant eligible and receiving consolidation and maintenance therapy, as well as the value of achieving sustained measurable residual disease (MRD) negativity. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.
